Akorn appoints Tom Moore and CEO Doug Boothe to its Board of Directors

– USA, IL – Akorn, Inc. (Nasdaq:AKRX), today announced that it has appointed Thomas G. Moore and its CEO Douglas S. Boothe to the Board of Directors of the Company, filling two new seats on the Board.

About Tom Moore

Mr. Moore, brings 35 years of strategic and operational pharmaceutical industry experience as a former executive at Abbott Laboratories, later known as Hospira, and its affiliates. Mr. Moore served as President of Hospira USA from 2009 until his retirement in 2014. He was President of Global Pharmaceuticals for Hospira Worldwide, Inc. from 2007 to 2009, and served as VP and General Manager of Specialty Pharmaceuticals for Hospira, Inc. from 2003 to 2007. Mr. Moore sits on the Board of Trustees for Rosalind Franklin University of Medicine and Science. Previously, Mr. Moore was a member of the boards of the Generic Pharmaceutical Association, the Society for Vascular Surgery, and XHOPL, Ltd., a joint venture corporation for the manufacturing of injectable oncology pharmaceuticals. Mr. Moore received his undergraduate degree from Loyola Marymount University Los Angeles, and his Doctor of Pharmacy from the University of Southern California.

“I am excited to have a leader of Chris’s caliber, with a track record of success in our industry, to lead our operations organization as we revitalize Akorn,” said President & CEO Doug Boothe. “Additionally, Tom Moore brings significant industry expertise to our Board of Directors. His first-hand experience navigating complex regulatory environments will be a tremendous resource for the Company.”

Additionally, the company announced that Christopher C. Young joins Akorn as Executive Vice President, Global Operations reporting to Douglas Boothe, President & Chief Executive Officer. Young brings twenty-five years of pharmaceutical experience to Akorn having most recently been the Executive Vice President of Global Operations for Alvogen, Inc. Prior to Alvogen, Young was Vice President of Operations in the United States and India for Actavis. He brings to Akorn a strong history of U.S. and global expertise in operations, supply chain, integration, remediation and operational excellence. His leadership and skills are well matched for the current challenges that the Company is facing with increased competition and a complex regulatory landscape. Young received his undergraduate degree from Gettysburg College and his MBA from Rutgers University.

About Akorn

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals.

For more information : http://www.akorn.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>